Publications by authors named "Elijah J Mun"
Background: Although polyp size dictates surveillance intervals, endoscopists often estimate polyp size inaccurately. We hypothesized that an intervention providing didactic instruction and real-time feedback could significantly improve polyp size classification.
Methods: We conducted a multicenter randomized controlled trial to evaluate the impact of different components of an online educational module on polyp sizing.
Recent advances and current challenges in endoscopic resection with the full-thickness resection device.
World J Gastroenterol
July 2023
Article Synopsis
- Endoscopic full-thickness resection (EFTR) is a new method for treating mucosal and subepithelial lesions in the gastrointestinal tract that traditional treatments can't address.
- The full-thickness resection device (FTRD system) by Ovesco Endoscopy AG has been developed for this purpose and was initially only available for use in the colorectum.
- A new version of the FTRD has recently been introduced for use in the upper gastrointestinal tract, and this review discusses its advancements as well as the challenges associated with it.
Background And Aims: Hepatocellular carcinoma (HCC) risk is high in cirrhosis. We sought to describe differences in HCC risk, predictors and trends over time according to etiology of cirrhosis.
Methods: We identified 116,404 patients with cirrhosis diagnosed between 2001-2014 in the VA healthcare system and determined incident HCC cases occurring from the date of cirrhosis diagnosis until 01/31/2017.
No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
Eur J Gastroenterol Hepatol
January 2019
Background And Aims: It is unclear whether there are differences between direct-acting antivirals (DAAs) for hepatitis C virus in risk of hepatocellular carcinoma (HCC) after antiviral therapy. We aimed to compare different DAA regimens with respect to risk of de novo HCC following antiviral therapy.
Patients And Methods: We identified 33 137 patients who initiated hepatitis C virus antiviral treatment in the Veterans Affair healthcare system between 6 December 2013 and 31 December 2015 with one of four DAA-only regimens (± ribavirin): paritaprevir/ritonavir/ombitasvir/dasabuvir (n=6289), sofosbuvir (n=4356), sofosbuvir+simeprevir (n=3210), and ledipasvir/sofosbuvir (n=19 282).
Background & Aims: Most patients with hepatitis C virus (HCV) infection will undergo antiviral treatment with direct-acting antivirals (DAAs) and achieve sustained virologic response (SVR). We aimed to develop models estimating hepatocellular carcinoma (HCC) risk after antiviral treatment.
Methods: We identified 45,810 patients who initiated antiviral treatment in the Veterans Affairs (VA) national healthcare system from 1/1/2009 to 12/31/2015, including 29,309 (64%) DAA-only regimens and 16,501 (36%) interferon ± DAA regimens.
Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells.
View Article and Find Full Text PDF